• Pacira Biosciences issued a rebuttal to DOMA Perpetual’s criticism of its EXPAREL intellectual property strategy, calling the claims inaccurate.
• It said the 2021–2024 EXPAREL patent litigation involved only the ’495 patent and carried no precedential value.
• Pacira said the ’495 patent was reissued following USPTO reexamination, with amended claims intended to address issues cited in the New Jersey ruling.
• It said a newer EXPAREL patent family led by the ’940 patent extends protection into July 2044 and has not been previously challenged.
• Pacira said the Fresenius Kabi settlement preserves EXPAREL exclusivity through early 2030, with a capped, gradual market entry until 2039.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.